Even 31% Seizure Reduction with CBD Was Clinically Meaningful for Lennox-Gastaut Patients
Post hoc analysis of two phase 3 trials found that a 31% reduction in drop seizures (not the traditional 50%) was the threshold for clinically meaningful improvement as rated by caregivers.
Quick Facts
What This Study Found
Using CGIC of 'slightly improved' or better, the threshold for clinically meaningful drop seizure reduction was 30.6%, with 57.7% of patients meeting this threshold. With 'much improved' or better, the threshold was 49.6% (40.5% of patients). 60% of CBD-treated patients were rated as 'slightly improved' or better, and 31% as 'much improved' or better after 14 weeks. Spearman's correlation between CGIC and seizure reduction was 0.47.
Key Numbers
215 patients with LGS. 60% rated 'slightly improved' or better. 31% rated 'much improved' or better. Clinically meaningful threshold: 30.6% reduction (57.7% met it). 'Much improved' threshold: 49.6% (40.5% met it). Mean seizure reduction for 'slightly improved+': 46.9%. Spearman's correlation: 0.47.
How They Did This
Post hoc analysis of 215 LGS patients receiving CBD (Epidiolex) from two phase 3 randomized placebo-controlled trials (NCT02224690 and NCT02224560). Drop seizure reduction anchored to Caregiver Global Impression of Change scores to determine clinically meaningful thresholds.
Why This Research Matters
Clinical trials typically use 50% seizure reduction as the success cutoff, but this analysis shows that caregivers perceived meaningful benefit at much smaller reductions (31%), suggesting the 50% threshold may undercount patients who genuinely benefit from treatment.
The Bigger Picture
By redefining what counts as a meaningful response, this analysis suggests CBD helps more LGS patients than traditional trial endpoints indicate. This has implications for insurance coverage, treatment continuation decisions, and regulatory assessments.
What This Study Doesn't Tell Us
Post hoc analysis with inherent limitations. CGIC is a single subjective rating. Only 14 weeks of data. Analysis of CBD-treated patients only (no placebo comparison for thresholds). Sample included wide age range (2-55 years). Exploratory nature limits definitive conclusions.
Questions This Raises
- ?Should clinical trials adopt lower seizure reduction thresholds?
- ?Do patients with 30-50% seizure reduction maintain benefits long-term?
Trust & Context
- Key Stat:
- Evidence Grade:
- Post hoc analysis of two phase 3 RCTs with validated caregiver assessments and appropriate statistical methodology supports strong evidence.
- Study Age:
- Data from phase 3 trials conducted April-December 2015.
- Original Title:
- Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.
- Published In:
- CNS drugs, 39(10), 1025-1036 (2025)
- Authors:
- Specchio, Nicola(3), Auvin, Stéphane(2), Greco, Teresa(2), Lagae, Lieven, Nortvedt, Charlotte, Zuberi, Sameer M
- Database ID:
- RTHC-07703
Evidence Hierarchy
Frequently Asked Questions
How much seizure reduction counts as helpful?
While clinical trials typically use a 50% reduction as the success benchmark, this analysis found caregivers perceived meaningful improvement at just 31% reduction in drop seizures, suggesting the traditional cutoff may be too strict.
Does CBD help most patients with Lennox-Gastaut syndrome?
60% of CBD-treated patients were rated as at least 'slightly improved' by caregivers, and 58% met the 31% seizure reduction threshold. This suggests a majority experience some meaningful benefit.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07703APA
Specchio, Nicola; Auvin, Stéphane; Greco, Teresa; Lagae, Lieven; Nortvedt, Charlotte; Zuberi, Sameer M. (2025). Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.. CNS drugs, 39(10), 1025-1036. https://doi.org/10.1007/s40263-025-01201-8
MLA
Specchio, Nicola, et al. "Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.." CNS drugs, 2025. https://doi.org/10.1007/s40263-025-01201-8
RethinkTHC
RethinkTHC Research Database. "Clinically Meaningful Reduction in Drop Seizures in Patients..." RTHC-07703. Retrieved from https://rethinkthc.com/research/specchio-2025-clinically-meaningful-reduction-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.